{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:11:21Z","timestamp":1794438681903,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 03.709"],"award-info":[{"award-number":["TTU 03.709"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EDCTP2","award":["ASAAP RIA2017MC-2022"],"award-info":[{"award-number":["ASAAP RIA2017MC-2022"]}]},{"DOI":"10.13039\/501100005711","name":"Universit\u00e4t Hamburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Malaria, especially caused by <jats:italic>Plasmodium falciparum<\/jats:italic>, remains a major global health concern, particularly in sub-Saharan Africa. To combat rising drug resistance, innovative treatment approaches like triple artemisinin-based combination therapy (TACT) and multi-drug antimalarial combination therapies (MDACTs) are being explored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study introduces a robust and validated multiplex LC\u2013MS\/MS assay for the simultaneous quantification of key antimalarial drugs and their metabolites, including artesunate, dihydroartemisinin, pyronaridine, proguanil, cycloguanil, and clindamycin. Developed in accordance with EMA guidelines, the assay ensures high accuracy, sensitivity, and stability. Serum samples were prepared through a process of protein precipitation with acetonitrile, followed by the evaporation of the supernatant. The resulting residues were then reconstituted in a 50\/50 mixture of aqueous 20\u00a0mM ammonium formate buffer and methanol for the analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The assay achieves lower limits of quantifications of 1\u00a0ng\/mL for proguanil, 0.2\u00a0ng\/mL for cycloguanil, 1\u00a0ng\/mL for artesunate, 4\u00a0ng\/mL for dihydroartemisinin, 2\u00a0ng\/mL for pyronaridine, and 5\u00a0ng\/mL for clindamycin. The assay was successfully applied in a pharmacokinetic study conducted as part of a clinical trial in Gabon and Ghana, assessing novel drug combinations in both children and adults against a standard of care artemisinin-based combination therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The developed assay can support the further clinical development of these TACTs and MDACTs, ultimately contributing to enhanced malaria treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12936-025-05387-6","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:38:00Z","timestamp":1748327880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multiplex LC\u2013MS\/MS assay for simultaneous quantification of artesunate and its active metabolite dihydroartemisinin with pyronaridine, proguanil, cycloguanil, and clindamycin in pharmacokinetic studies"],"prefix":"10.1186","volume":"24","author":[{"given":"Christoph","family":"Pfaffendorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Mischlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Dejon-Agob\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumou","family":"Ma\u00efga-Ascofar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Ahenkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u00f4la Akim","family":"Adegnika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G.","family":"Wicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"5387_CR1","unstructured":"WHO. World malaria report 2023. Geneva: World Health Organization; 2023. https:\/\/www.who.int\/publications\/i\/item\/9789240086173. Accessed 22 Aug 2024."},{"key":"5387_CR2","unstructured":"WHO. Antimalarial drug combination therapy. Geneva: World Health Organization; 2001. https:\/\/iris.who.int\/bitstream\/handle\/10665\/66952\/WHO_CDS_RBM_2001.35.pdf?sequence=1. Accessed 6 Aug 2024."},{"key":"5387_CR3","unstructured":"WHO. Guidelines for malaria. Geneva: World Health Organization; 2023. https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria. Accessed 6 Aug 2024."},{"key":"5387_CR4","doi-asserted-by":"publisher","first-page":"146339","DOI":"10.1016\/j.gene.2022.146339","volume":"821","author":"FN Nkemngo","year":"2022","unstructured":"Nkemngo FN, Mugenzi LMJ, Tchouakui M, Nguiffo-Nguete D, Wondji MJ, Mbakam B, et al. Xeno-monitoring of molecular drivers of artemisinin and partner drug resistance in P. falciparum populations in malaria vectors across Cameroon. Gene. 2022;821:146339.","journal-title":"Gene."},{"key":"5387_CR5","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13:6353.","journal-title":"Nat Commun"},{"key":"5387_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, ul Islam A, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395:1345\u201360.","journal-title":"Lancet."},{"key":"5387_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12936-022-04079-9","volume":"21","author":"Q Bassat","year":"2022","unstructured":"Bassat Q, Ma\u00efga-Ascofar\u00e9 O, May J, Clain J, Mombo-Ngoma G, Groger M, et al. Challenges in the clinical development pathway for triple and multiple drug combinations in the treatment of uncomplicated falciparum malaria. Malar J. 2022;21:61.","journal-title":"Malar J"},{"key":"5387_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jchromb.2008.10.018","volume":"876","author":"W Hanpithakpong","year":"2008","unstructured":"Hanpithakpong W, Kamanikom B, Dondorp AM, Singhasivanon P, White NJ, Day NPJ, et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr, B: Anal Technol Biomed Life Sci. 2008;876:61\u20138.","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"5387_CR9","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1007\/s00216-014-7820-x","volume":"406","author":"MCK Geditz","year":"2014","unstructured":"Geditz MCK, Heinkele G, Ahmed A, Kremsner PG, Kerb R, Schwab M, et al. LC-MS\/MS method for the simultaneous quantification of artesunate and its metabolites dihydroartemisinin and dihydroartemisinin glucuronide in human plasma. Anal Bioanal Chem. 2014;406:4299\u2013308.","journal-title":"Anal Bioanal Chem"},{"key":"5387_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jchromb.2009.02.006","volume":"877","author":"EM Hodel","year":"2009","unstructured":"Hodel EM, Zanolari B, Mercier T, Biollaz J, Keiser J, Olliaro P, et al. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:867\u201386.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5387_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpba.2017.08.023","volume":"146","author":"D Blessborn","year":"2017","unstructured":"Blessborn D, Kaewkhao K, Song L, White NJ, Day NPJ, Tarning J. Quantification of the antimalarial drug pyronaridine in whole blood using LC\u2013MS\/MS\u2014increased sensitivity resulting from reduced non-specific binding. J Pharm Biomed Anal. 2017;146:214\u20139.","journal-title":"J Pharm Biomed Anal"},{"key":"5387_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0378-4347(00)00512-0","volume":"752","author":"YC Chen","year":"2001","unstructured":"Chen YC, Fleckenstein L. Improved assay method for the determination of pyronaridine in plasma and whole blood by high-performance liquid chromatography for application to clinical pharmacokinetic studies. J Chromatogr B Biomed Sci Appl. 2001;752:39\u201346.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"5387_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1365\/s10337-009-1259-9","volume":"70","author":"SG Pingale","year":"2009","unstructured":"Pingale SG, Nerurkar KK, Padgaonkar AM, Pawar UD, Mangaonkar KV. Alternative LC-MS-MS method for simultaneous determination of proguanil, its active metabolite in human plasma and application to a bioequivalence study. Chromatographia. 2009;70:1095\u2013102.","journal-title":"Chromatographia"},{"key":"5387_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jchromb.2005.11.004","volume":"830","author":"NL Leveque","year":"2006","unstructured":"Leveque NL, Charman WN, Chiu FCK. Sensitive method for the quantitative determination of proguanil and its metabolites in rat blood and plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:314\u201321.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5387_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/rcm.887","volume":"17","author":"GN Rechberger","year":"2003","unstructured":"Rechberger GN, Fauler G, Windischhofer W, K\u00f6feler H, Erwa W, Leis HJ. Quantitative analysis of clindamycin in human plasma by liquid chromatography\/electrospray ionisation tandem mass spectrometry using d1-N-ethylclindamycin as internal standard. Rapid Commun Mass Spectrom. 2003;17:135\u20139.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"5387_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0378-4347(99)00018-3","volume":"724","author":"LL Yu","year":"1999","unstructured":"Yu LL, Chao CK, Liao WJ, Twu TY, Liu CM, Yang TH, et al. Determination of clindamycin in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to the bioequivalence study of clindamycin. J Chromatogr B Biomed Sci Appl. 1999;724:287\u201394.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"5387_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116154","volume":"245","author":"WM Schouten","year":"2024","unstructured":"Schouten WM, Roseboom IC, Lucas L, Kabalu Tshiongo J, Muhindo Mavoko H, Kayentao K, et al. Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood. J Pharm Biomed Anal. 2024;245: 116154.","journal-title":"J Pharm Biomed Anal"},{"key":"5387_CR18","doi-asserted-by":"publisher","first-page":"1044234","DOI":"10.3389\/fphar.2022.1044234","volume":"13","author":"W Lu","year":"2022","unstructured":"Lu W, Pan M, Ke H, Liang J, Liang W, Yu P, et al. An LC-MS\/MS method for the simultaneous determination of 18 antibacterial drugs in human plasma and its application in therapeutic drug monitoring. Front Pharmacol. 2022;13:1044234.","journal-title":"Front Pharmacol"},{"key":"5387_CR19","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf. Accessed 23 Jan 2025."},{"key":"5387_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin C-S, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"key":"5387_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1570-0232(03)00591-9","volume":"795","author":"CP Babalola","year":"2003","unstructured":"Babalola CP, Scriba GKE, Sowunmi A, Alawode OA. Liquid chromatographic determination of pyronaridine in human plasma and oral dosage form. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;795:265\u201372.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5387_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0378-4347(96)00410-0","volume":"690","author":"SD Jayaraman","year":"1997","unstructured":"Jayaraman SD, Ismail S, Nair NK, Navaratnam V. Determination of pyronaridine in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. J Chromatogr B Biomed Sci Appl. 1997;690:253\u20137.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"5387_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jchromb.2005.06.034","volume":"824","author":"S Ramanathan","year":"2005","unstructured":"Ramanathan S, Karupiah S, Nair NK, Olliaro PL, Navaratnam V, Wernsdorfer WH, et al. A new and simple solid-phase extraction method for LC determination of pyronaridine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;824:45\u201350.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5387_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0035-9203(98)90749-0","volume":"92","author":"A Sabchareon","year":"1998","unstructured":"Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1998;92:201\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5387_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1475-2875-6-70","volume":"6","author":"K Na-Bangchang","year":"2007","unstructured":"Na-Bangchang K, Ruengweerayut R, Karbwang J, Chauemung A, Hutchinson D. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar J. 2007;6:70.","journal-title":"Malar J"},{"key":"5387_CR26","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.3390\/molecules15128747","volume":"15","author":"P Teja-Isavadharm","year":"2010","unstructured":"Teja-Isavadharm P, Siriyanonda D, Siripokasupkul R, Apinan R, Chanarat N, Lim A, et al. A simplified liquid chromatography-mass spectrometry assay for artesunate and dihydroartemisinin, its metabolite, in human plasma. Molecules. 2010;15:8747\u201368.","journal-title":"Molecules"},{"key":"5387_CR27","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/bmc.517","volume":"19","author":"S-H Cho","year":"2005","unstructured":"Cho S-H, Im H-T, Park W, Ha Y-H, Choi Y-W, Lee K-T. Simple method for the assay of clindamycin in human plasma by reversed-phase high-performance liquid chromatography with UV detector. Biomed Chromatogr. 2005;19:783\u20137.","journal-title":"Biomed Chromatogr"},{"key":"5387_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jchromb.2008.10.021","volume":"876","author":"N Lindegardh","year":"2008","unstructured":"Lindegardh N, Hanpithakpong W, Kamanikom B, Singhasivanon P, Socheat D, Yi P, et al. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876:54\u201360.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5387_CR29","first-page":"177","volume":"37","author":"K Na-Bangchang","year":"2006","unstructured":"Na-Bangchang K, Banmairuroi V, Kamanikom B, Kiod D. An alternative high-performance liquid chromatographic method for determination of clindamycin in plasma. Southeast Asian J Trop Med Public Health. 2006;37:177\u201384.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"5387_CR30","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/jac\/dkad260","volume":"78","author":"W-Y Chu","year":"2023","unstructured":"Chu W-Y, Dorlo TPC. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria. J Antimicrob Chemother. 2023;78:2406\u201318.","journal-title":"J Antimicrob Chemother"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05387-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:02:15Z","timestamp":1748372535000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05387-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5387"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05387-6","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study conformed to the Declaration of Helsinki and Standard Operating Procedures that meet current regulatory requirements and guidelines laid down by the International Conference on Harmonisation for Good Clinical Practice in Clinical Studies. The clinical trial was approved by the relevant Independent Ethics Committees, national Institutional Review Boards, and local regulatory authorities at Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9 (CERMEL) (Lambar\u00e9n\u00e9, Gabon). The study protocol was registered online before start of recruitment into this clinical trial (pactr.samrc.ac.za, PACTR202008909968293).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}